![Blood Podcast artwork](https://is1-ssl.mzstatic.com/image/thumb/Podcasts113/v4/02/82/f4/0282f4cd-40ab-c4eb-7ebd-ab26ffec617e/mza_15952236382953722746.jpg/100x100bb.jpg)
Danicopan add-on therapy in PNH, neural networks to identify bone marrow cells, and RNA editome and hematopoiesis
Blood Podcast
English - November 18, 2021 17:30 - 17 minutes - 16.2 MB - ★★★★ - 44 ratingsLife Sciences Science hematology oncology medical medical research Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed
In this week’s episode, we’ll review results of a phase 2 study showing the beneficial effects of a first-in-class factor D inhibitor as add-on therapy in PNH patients who remain anemic and are transfusion-dependent despite C5 inhibition. Next, we’ll review the work of researchers who have developed a neural network that they say is highly accurate in differentiating between bone marrow cell morphologies. We’ll close with a report demonstrating that RNA editing of antizyme inhibitor 1, or Azin1, is a novel regulator of hematopoietic cell fate that can influence self-renewal and differentiation.